The Adiponectin Receptor Agonist, ALY688: A Promising Therapeutic for Fibrosis in the Dystrophic Muscle

• Published in: Cells (Basel, Switzerland) Vol. 12; no. 16; p. 2101
• Main Authors: Dubuisson, Nicolas, Versele, Romain, Davis-López de Carrizosa, Maria A, Selvais, Camille M, Noel, Laurence, Planchon, Chloé, Van den Bergh, Peter Y. K, Brichard, Sonia M, Abou-Samra, Michel
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 01.08.2023; MDPI
• Subjects: Adiponectin; Agonists; ALY688; AMPK; Analysis; Antibodies; Care and treatment; Development and progression; Diagnosis; Duchenne muscular dystrophy; Duchenne's muscular dystrophy; Fibrosis; Fitness equipment; Inflammation; Metabolism; Musculoskeletal system; Mutation; Myonecrosis; Myotubes; Necroptosis; Oxidative stress; Pathophysiology; Phenotype; Phenotypes; skeletal muscle; Transforming growth factor-b; Transforming growth factors; Spain; United Kingdom > UK; United States > US
• ISSN: 2073-4409; 2073-4409
• DOI: 10.3390/cells12162101

Duchenne muscular dystrophy (DMD) is one of the most devastating myopathies, where severe inflammation exacerbates disease progression. Previously, we demonstrated that adiponectin (ApN), a hormone with powerful pleiotropic effects, can efficiently improve the dystrophic phenotype. However, its practical therapeutic application is limited. In this study, we investigated ALY688, a small peptide ApN receptor agonist, as a potential novel treatment for DMD. Four-week-old mdx mice were subcutaneously treated for two months with ALY688 and then compared to untreated mdx and wild-type mice. In vivo and ex vivo tests were performed to assess muscle function and pathophysiology. Additionally, in vitro tests were conducted on human DMD myotubes. Our results showed that ALY688 significantly improved the physical performance of mice and exerted potent anti-inflammatory, anti-oxidative and anti-fibrotic actions on the dystrophic muscle. Additionally, ALY688 hampered myonecrosis, partly mediated by necroptosis, and enhanced the myogenic program. Some of these effects were also recapitulated in human DMD myotubes. ALY688’s protective and beneficial properties were mainly mediated by the AMPK-PGC-1α axis, which led to suppression of NF-κβ and TGF-β. Our results demonstrate that an ApN mimic may be a promising and effective therapeutic prospect for a better management of DMD.